UPTD vs. AIM, NKGN, CLDI, SRNE, GNCAQ, GNCA, ELOX, PRME, JATT, and IKT
Should you be buying TradeUP Acquisition stock or one of its competitors? The main competitors of TradeUP Acquisition include AIM ImmunoTech (AIM), NKGen Biotech (NKGN), Calidi Biotherapeutics (CLDI), Sorrento Therapeutics (SRNE), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), JATT Acquisition (JATT), and Inhibikase Therapeutics (IKT). These companies are all part of the "biological products, except diagnostic" industry.
TradeUP Acquisition vs. Its Competitors
AIM ImmunoTech (NYSE:AIM) and TradeUP Acquisition (NASDAQ:UPTD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.
AIM ImmunoTech currently has a consensus target price of $275.00, suggesting a potential upside of 10,476.92%. Given AIM ImmunoTech's stronger consensus rating and higher probable upside, equities analysts clearly believe AIM ImmunoTech is more favorable than TradeUP Acquisition.
TradeUP Acquisition has lower revenue, but higher earnings than AIM ImmunoTech.
TradeUP Acquisition has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. TradeUP Acquisition's return on equity of 0.00% beat AIM ImmunoTech's return on equity.
AIM ImmunoTech has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, TradeUP Acquisition has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500.
12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 35.0% of TradeUP Acquisition shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 55.1% of TradeUP Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, AIM ImmunoTech had 2 more articles in the media than TradeUP Acquisition. MarketBeat recorded 2 mentions for AIM ImmunoTech and 0 mentions for TradeUP Acquisition. TradeUP Acquisition's average media sentiment score of 0.67 beat AIM ImmunoTech's score of 0.00 indicating that TradeUP Acquisition is being referred to more favorably in the news media.
Summary
AIM ImmunoTech and TradeUP Acquisition tied by winning 7 of the 14 factors compared between the two stocks.
Get TradeUP Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPTD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding UPTD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TradeUP Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:UPTD) was last updated on 9/14/2025 by MarketBeat.com Staff
Free UPTD Stock Alerts